What You Ought to Know:
– Immunai, a number one AI biotech firm specializing in mapping the human immune system and the Parker Institute for Most cancers Immunotherapy (PICI), a collaborative consortium of the world’s main immuno-oncology consultants, introduced right now that they’ll construct the world’s largest single-cell dataset from sufferers handled with standard-of-care (SoC) immunotherapy.
– Below the collaboration with PICI, Immunai will carry out single-cell RNA sequencing (scRNA-seq) and multi-omic profiling of affected person blood samples collected from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Sufferers Interrogated by Harmonized Molecular Datasets) cohort, a potential longitudinal examine of 1,070 sufferers receiving immune checkpoint inhibitor therapy regimens in a neighborhood setting.
Immunai Expands AMICA™ with Trade’s Largest Actual-World Single-Cell Dataset in Immuno-Oncology
Immunai, a biotechnology firm leveraging single-cell genomics and machine studying to remodel therapeutic growth, has introduced a significant growth of its AMICA™ (Annotated Multi-omic Immune Cell Atlas) platform. This growth will combine the most important single-cell dataset of standard-of-care (SoC) comparators in immuno-oncology, considerably enhancing AMICA’s benchmarking energy and translational relevance.
The initiative makes use of 10x Genomics’ Chromium GEM-X single-cell expertise to assist high-throughput, cost-effective pattern processing, enabling the technology of high-quality single-cell knowledge at scale. This dataset will probably be absolutely embedded inside AMICA™, strengthening its analytical capabilities and positioning it as probably the most complete immune cell atlas out there for oncology analysis.
The expanded dataset will broaden entry to immunotherapy response profiles throughout a various vary of tumor varieties—together with non-small cell lung most cancers (NSCLC), small cell lung most cancers (SCLC), gastric most cancers, hepatocellular carcinoma (HCC), and melanoma. This may assist the identification of clinically distinct affected person subgroups by:
- facilitating the invention of predictive biomarkers,
- enabling deeper understanding of mechanisms of motion and resistance,
- and bettering characterization of affected person responses in real-world contexts.
By integrating hundreds of real-world samples, AMICA™ affords a extra consultant view of immune responses, closing the hole between managed medical trials and routine medical follow. Its embedded machine studying instruments additional speed up insights from this knowledge, guiding drug builders in figuring out not solely which sufferers are most certainly to learn from rising remedies but in addition the place therapies could also be ineffective or require modification.
“There’s an enormous hole between what we be taught in managed trials and what occurs in real-world affected person care,” stated Noam Solomon, PhD, CEO and Co-Founding father of Immunai. “By including hundreds of real-world samples to AMICA, we’re giving scientists and drug builders the ability to identify the affected person teams most certainly to learn from new remedies—and maybe extra importantly, the place they won’t.”
With over 170 group members, together with 85 PhDs and MDs, and near $270 million in funding, Immunai continues to collaborate with main pharmaceutical corporations and educational establishments. Headquartered in New York Metropolis, the corporate stays on the forefront of unlocking the immune system’s potential to information precision therapies via data-driven discovery.
